beta-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia
P Bourgeat, G Chetelat, VL Villemagne, J Fripp, P Raniga, K Pike, O Acosta, C Szoeke, S Ourselin, D Ames, KA Ellis, RN Martins, CL Masters, CC Rowe, O Salvado, AIBL Res Grp
Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2010
The Australian Imaging, Biomarkers and Lifestyle Research Group receives funding from the Commonwealth Scientific and Industrial Research Organisation. Dr. Szoekes' research has been supported by the Alzheimer's Association of Australia and the National Health and Medical Research Council.Dr. Bourgeat and Dr. Chetelat report no disclosures. Dr. Villemagne serves as a consultant to Bayer Schering Pharma. Dr. Fripp, Dr. Raniga, Dr. Pike, and Dr. Acosta report no disclosures. Dr. Szoeke may accrue revenue on a pending patent (filed: 2003): diagnostic assay for seizure prediction; and has received speaker honoraria from Pfizer Inc and Lundbeck Inc. Dr. Ourselin reports no disclosures. Dr. Ames has served/serves on scientific advisory boards for Novartis, Janssen, and Pfizer Inc; has received funding for travel from Janssen and Pfizer Inc; serves as Editorin-Chief of International Psychogeriatrics; receives royalties from publishing Dementia, 3rd ed. (Hodder Arnold, 2005); has received speaker honoraria from Pfizer and Lundbeck; and receives research support from Eli Lilly and Company, GlaxoSmithKline, Novartis, and Forest Laboratories, Inc. Dr. Ellis reports no disclosures. Dr. Martins serves as Senior Editor of the Journal of Alzheimer's Disease; and serves as a consultant to and holds stock in Alzhyme. Dr. Masters, Dr. Rowe, and Dr. Salvado report no disclosures.